Articles On Telix Pharmaceuticals (ASX:TLX)

The last financial year was a good one for the S&P/ASX 200 Index (ASX: XJO). The benchmark index carved out a sizeable return of 9.7% for the period. While this was strong, some ASX 200 shares delivered even stronger gains. Here’s...

It has been another busy week for Australia’s top brokers. This has led to the release of a large number of broker notes. Three broker buy ratings that you might want to know more about are summarised below. Here’s why brokers think th...

On Thursday, the S&P/ASX 200 Index (ASX: XJO) ran out of steam and edged into the red. The benchmark index fell slightly to 7,194.9 points. Will the market be able to bounce back from this on Friday? Here are five things to watch: AS...

Telix (ASX:TLX) has released further details of the positive results from its completed pivotal Phase 3 ZIRCON study of TLX250-CDx in clear cell renal cell carcinoma.

MELBOURNE, Australia, June 27, 2023 /PRNewswire/ — Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces further details of the positive results from its completed pivotal Phase III ZIRCON study of TLX250-CDx (89Zr...

Wilsons equity strategist Rob Crookston is a happy man. Despite the turbulence in the general market, many of his team’s S&P/ASX 200 Index (ASX: XJO) holdings in the focus portfolio enjoyed earnings upgrades in recent times. Like a pro...

Avita Medical receives US FDA premarket approval for its RECELL System to treat vitiligo Telix will buy UK medical device firm Lightpoint Medical and its radio-guided surgery business SENSEI Antisense in strong position with new CEO, forme...

The Imugene Limited (ASX: IMU) share price has continued downward in the last 12 months, with the clinical-stage immuno-oncology company declining further in 2023. Unlike the reasonable 3.5% return of the S&P/ASX All Ordinaries Index...

MELBOURNE, Australia, June 22, 2023 /PRNewswire/ — Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces presentations from the Company’s investigational prostate (prostate specific-membrane antigen, or PSMA-target...

After the S&P/ASX 200 Index (ASX: XJO) broke its near-two week winning streak yesterday, the index today sadly doubled down on those losses. The ASX 200 finished deep in red territory this Thursday. By the end of trading, the index...

MELBOURNE, Australia, June 21, 2023 /PRNewswire/ – Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces it has entered into an agreement to acquire Lightpoint Medical and its SENSEI® radio-guided surgery business....

The S&P/ASX 200 Index (ASX: XJO) has sadly broken its near-two-week winning streak this Wednesday. After recording a gain every single session since Thursday 8 June, the ASX 200 finished up in the red today. The index closed up shop...

The ASX 200 index slumped by almost half a percent Energy stocks retreated, while Telstra, QBE, Woolworths, and IAG touched new highs Bitcoin has also hit a six-week high   The ASX slipped half a percentage point on Wednesday as traders d...

MELBOURNE, Australia and INDIANAPOLIS, June 21, 2023 /PRNewswire/ — Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today provides an outline agenda for the Company’s briefing session for shareholders to be held on Wednesday...

Brisbane-based biotech Vaxxas is working on needles-free vaccine The Nanopatch is said to be a “game changer” We look at the best and worst performing ASX biotechs over the past month   The world is anticipating a “game changer” as Brisba...

Telix (ASX:TLX) has announced that the first patient has been dosed in a global Phase 2 study of its imaging agent TLX250-CDx (89Zr-DFO-girentuximab).

The ASX was trading positively at midday, up almost 0.7 per cent. Most sectors secured gains, with healthcare leading the pack, up nearly two per cent at midday. In ASX news, Iceni Gold (ICL) has made further gold finds along the 15-...

Telix Pharmaceuticals (TLX) doses the first patient for its phase II Starburst study for treating a broad range of cancers The study will look to test the effects of its carbonic anhydrase (CAIX) targeting PET/CT imaging agent TLX250-CD...

MELBOURNE, Australia, June 19, 2023 /PRNewswire/ — Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that the first patient has been dosed in a Phase II study of the Company’s carbonic anhydrase- (CAIX)-targeti...

The S&P/ASX 200 Index (ASX: XJO) has ended the trading week on a very high high this Friday. Not only did today’s session mark the ASX’s fifth straight day of gains in a row, but it also left the index at a three-week high. The ASX...

June 21, 2023, at The Yale Club, New York City  Featured speakers and Key Opinion Leaders include: Dr Christian Behrenbruch, Dr Colin Hayward, Kevin Richardson, Dr Brian Shuch and Dr Scott Tagawa Topics include Telix’s urologic pipeline,...

The S&P/ASX 200 Index (ASX: XJO) has closed after another positive session this Wednesday. Following the ASX 200‘s late return to trading this week (thanks to the King’s Birthday holiday), the index ended up adding a healthy 0.32% to...

After a shaky start in the red this morning, the S&P/ASX 200 Index (ASX: XJO) ended up closing higher on Tuesday afternoon. The ASX 200 finished the day at 7,138.9 points, a gain of 0.23% These gains might have been helped by last week...

Telix (ASX:TLX) has officially opened its radiopharmaceutical production facility in Brussels South (Seneffe), in the Wallonia region of Belgium.

Australia’s second-largest biotechnology company by revenue behind CSL (ASX: CSL), Telix Pharmaceuticals (ASX: TLX) opened a world-class radiopharmaceutical nuclear medicine facility in Belgium on Thursday. The $21 million facility will se...

Telix has unveiled its new, state-of-art radiopharmaceutical facility in Brussels South as part of its first stage investment of €14.1 million ($A21.2 million)    Located in Walloon’s ‘Radiopharma Valley’ the facility will be a central...

MELBOURNE, Australia, June 6, 2023 /PRNewswire/ — Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today advises that Dr Christian Behrenbruch, Managing Director and Group CEO, will be presenting at the Jefferies Healthcare C...

The final day of the trading week saw the ASX finish in the green up 0.48 per cent. This comes after the US senate voted to suspend the country’s debt ceiling until 2025, avoiding a potentially catastrophic default. In the green U...

After starting the day off on the wrong foot, the S&P/ASX 200 Index (ASX: XJO) tumbled even further this afternoon to close the day 1.48% lower at 7,102.8 points. The apparent driver of its tumble was the latest Aussie inflation figur...

The S&P/ASX 200 Index (ASX: XJO) traded in the red for much of Tuesday, ending the session 0.11% lower at 7,209.3 points. It came on the back of various public holidays in the United States, the United Kingdom, and Germany on Monday. T...

It has been a great start to the week for the S&P/ASX 200 Index (ASX: XJO). In afternoon trade, the benchmark index is up 1.1% to 7,231.2 points. Four ASX shares that have failed to follow the market higher today are listed below. Her...

June 21, 2023, at The Yale Club, New York City The Company will showcase its urologic pipeline, development of novel therapeutics, imaging agents and technologies that aim to harness the power of targeted radiation at every step of the p...

The S&P/ASX 200 Index (ASX: XJO) tumbled on Thursday, falling 1.05% to close at 7,138.2 points. The market’s suffering came amid continued concerns of the United States’ rapidly approaching debt ceiling, as my Fool colleague Bernd...

World Overnight SPI Overnight 7241.00 – 35.00 – 0.48% S&P ASX 200 7259.90 – 3.40 – 0.05% S&P500 4145.58 – 47.05 – 1.12% Nasdaq Comp 12560.25 – 160.53 – 1.26% DJIA 33055.51 – 231.07 – 0.69% S&P500 VIX 18.53 + 1.32 7...

After spending all day in the green, the S&P/ASX 200 Index (ASX: XJO) posted a last-minute fall on Tuesday, dropping 0.05% to close at 7,259.9 points. It followed a mixed performance on Wall Street overnight. The Dow Jones Industrial...

The S&P/ASX 200 Index (ASX: XJO) is in the green on Tuesday, thanks in part to three stocks each soaring to new all-time record highs. So, what’s been going right for the trio lately? Let’s take a look. 3 ASX 200 shares reaching re...

The S&P/ASX 200 Index (ASX: XJO) spent Tuesday in the red, closing the day 0.45% lower at 7,234.7 points. And there were plenty of sectors weighing it down. The S&P/ASX 200 Consumer Staples Index (ASX: XSJ) was its worst performer....

Maybe you are sick of hearing this, but it doesn’t make it any less true: it’s a turbulent time for ASX shares at the moment. With much of the world still struggling with both high inflation and steep interest rate rises, it’s touch-and-go...

The S&P/ASX 200 Index (ASX: XJO) slipped lower once more on Thursday, falling 0.05% to close at 7,251.9 points. Weighing it down was the S&P/ASX 200 Materials Index (ASX: XMJ), which slumped 0.4% despite a ripper performance from...

The S&P/ASX 200 Index (ASX: XJO) slumped on Wednesday, dropping 0.12% to close at 7,255.7 points. Its day in the red came on the back of the 2023 federal budget, delivered on Tuesday night. It included $14.6 billion of spending aimed a...

S&P/ASX 300 Index (ASX: XKO) shares have returned an average of 18.8% over the past five years. Of course, some stocks have exceeded those gains while others have lost value over this time. Below, we look at three ASX 300 shares that w...

Telix (ASX:TLX) has agreed with Bayer to supply its Illuccix for a Phase 3 ARASTEP study investigating the efficacy of the German company's Nubeqa (darolutamide) plus androgen deprivation therapy in hormone-sensitive prostate cancer...

MELBOURNE, Australia, May 8, 2023 /PRNewswire/ — Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that it has entered into an agreement with Bayer AG (Bayer) to supply Illuccix® (TLX591-CDx, kit for the prepar...

MELBOURNE, Australia and KYOTO, Japan, May 8, 2023 /PRNewswire/ — Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that it has entered into an agreement with Bayer AG (Bayer) to supply Illuccix® (TLX591-CDx, k...

ASX 200 healthcare share Telix Pharmaceuticals Ltd (ASX: TLX) has had a stellar month. The Telix Pharmaceuticals share price has soared 53% from $7.01 at market close on 3 April to $10.745 at the time of writing. For perspective, the S&am...

The S&P/ASX 200 Index (ASX: XJO) plummeted on Tuesday, dropping 0.92% to finish the session at 7,267.4 points. Its day in the red came amid the Reserve Bank of Australia (RBA) board’s May meeting, wherein it hiked interest rates once...

MELBOURNE, Australia, May 2, 2023 /PRNewswire/ – Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces first patients have been imaged in Canada with its commercially available prostate cancer imaging agent, Illucc...

The ASX jumped half a percent, tracking moves in New York on Friday Three major decisions by central banks this week Judo Capital upgrades its net interest margin guidance for H2    The ASX 200 index rose to by 0.5% on Tuesday as it track...

The S&P/ASX 200 Index (ASX: XJO) has started the week in a positive fashion. In afternoon trade, the benchmark index is currently up 0.5% to 7,343.3 points. Four ASX shares that are climbing more than most today are listed below. Her...

Telix Pharmaceuticals (TLX) reveals new “positive” results from its phase III ZIRCON study of its TLX250-CDx imaging agent in clear cell renal cell carcinoma (ccRCC) TLX says the study shows the “high value” of its agent in detecting cc...